Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients

The tumor biology of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) promotes the development of central nervous system (CNS) metastases, with 25% of patients with HER2-positive BC developing CNS metastases. Furthermore, the incidence of HER2-positive BC brain metastases...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2023-08, Vol.40 (8), p.3304-3331
Main Authors: Galve-Calvo, Elena, Alonso-Babarro, Alberto, Martínez-García, María, Pi-Figueras, María, Villalba, Gloria, Alonso, Saioa, Contreras, Jorge
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - therapeutic use
Brain Neoplasms - therapy
Breast Neoplasms - drug therapy
Cardiology
Cranial Irradiation
Endocrinology
Female
Humans
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Pharmacology/Toxicology
Quality of Life
Receptor, ErbB-2 - metabolism
Review
Rheumatology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The tumor biology of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) promotes the development of central nervous system (CNS) metastases, with 25% of patients with HER2-positive BC developing CNS metastases. Furthermore, the incidence of HER2-positive BC brain metastases has increased in the last decades, likely because of the improved survival with targeted therapies and better detection methods. Brain metastases are detrimental to quality of life and survival and represent a challenging clinical problem, particularly in elderly women, who comprise a substantial proportion of patients diagnosed with BC and often have comorbidities or an age-related decline in organ function. Treatment options for patients with BC brain metastases include surgical resection, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy, and targeted agents. Ideally, local and systemic treatment decisions should be made by a multidisciplinary team, with input from several specialties, based on an individualized prognostic classification. In elderly patients with BC, additional age-associated conditions, such as geriatric syndromes or comorbidities, and the physiologic changes associated with aging, may impact their ability to tolerate cancer therapy and should be considered in the treatment decision-making process. This review describes the treatment options for elderly patients with HER2-positive BC and brain metastases, focusing on the importance of multidisciplinary management, the different points of view from the distinct disciplines, and the role of oncogeriatric and palliative care in this vulnerable patient group.
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-023-02538-6